Copyright © Inderes 2011 - present. All rights reserved.
  • Uusimmat
  • Pörssi
    • Aamukatsaus
    • Osakevertailu
    • Pörssikalenteri
    • Osinkokalenteri
    • Analyysi
    • Artikkelit
    • Sisäpiirin kaupat
  • inderesTV
  • Mallisalkku
  • Foorumi
  • Premium
  • Femme
  • Opi
    • Sijoituskoulu
    • Q&A
    • Analyysikoulu
  • Meistä
    • Seurantayhtiöt
    • Tiimi
Pörssitiedote

Invitation to webinar in connection with Lumito AB’s Q3 2025 Interim Report

Lumito
Lataa tiedote

Lumito AB (publ) (“Lumito” or the “Company”) will publish its report for the third quarter of 2025 on 27 November 2025. In connection with the publication, shareholders, investors, and other stakeholders are invited to a webinar on the same day at 14:00 CET.

During the session, the Company’s CEO, Sanna Wallenborg, will provide a brief introduction to Lumito and summarise the key events of the quarter. This will be followed by an overview of the financial results for the period. The webinar will conclude with a Q&A session, where Sanna Wallenborg and CFO Fata Mrsic will respond to questions submitted in advance to ir@lumito.se.
 
The presentation will be held in Swedish.

A recording of the webinar, including the Q&A, will be made available on the Company’s website after the event.
 
Date and time: 27 November 2025 at 14:00 CET
Registration: https://events.teams.microsoft.com/event/729dc3c3-5426-47a3-b889-1a2db3800491@93b12032-4992-4d22-8a2c-445707f886f0

For further information, please contact:


Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68

About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments
Invitation to webinar in connection with Lumito AB’s Q3 2025 Interim Report

Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke
Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.